| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer K Berns, HM Horlings, BT Hennessy, M Madiredjo, EM Hijmans, K Beelen, ... Cancer cell 12 (4), 395-402, 2007 | 1820 | 2007 |
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer K Berns, HM Horlings, BT Hennessy, M Madiredjo, EM Hijmans, K Beelen, ... Cancer cell 12 (4), 395-402, 2007 | 1820 | 2007 |
| Molecular characterisation of soft tissue tumours: a gene expression study TO Nielsen, RB West, SC Linn, O Alter, MA Knowling, JX O'Connell, S Zhu, ... The Lancet 359 (9314), 1301-1307, 2002 | 732 | 2002 |
| Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model R Meuwissen, SC Linn, RI Linnoila, J Zevenhoven, WJ Mooi, A Berns Cancer cell 4 (3), 181-189, 2003 | 600 | 2003 |
| Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ... Nature medicine 25 (6), 920-928, 2019 | 562 | 2019 |
| 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study MC van Maaren, L de Munck, GH de Bock, JJ Jobsen, T van Dalen, ... The Lancet Oncology 17 (8), 1158-1170, 2016 | 355 | 2016 |
| An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients MJB Taphoorn, L Claassens, NK Aaronson, C Coens, M Mauer, D Osoba, ... European Journal of Cancer 46 (6), 1033-1040, 2010 | 347* | 2010 |
| Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study F Amant, G von Minckwitz, SN Han, M Bontenbal, AE Ring, J Giermek, ... J Clin Oncol 31 (20), 2532-2539, 2013 | 338 | 2013 |
| Treatment of breast cancer during pregnancy: an observational study S Loibl, SN Han, G von Minckwitz, M Bontenbal, A Ring, J Giermek, ... The lancet oncology 13 (9), 887-896, 2012 | 337 | 2012 |
| Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ... The lancet oncology 8 (12), 1079-1087, 2007 | 332 | 2007 |
| The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer M Knauer, S Mook, EJT Rutgers, RA Bender, M Hauptmann, ... Breast cancer research and treatment 120, 655-661, 2010 | 319 | 2010 |
| Effects of tamoxifen and exemestane on cognitive functioning: a study in postmenopausal CMT Schilder | 290 | 2010 |
| A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ... International journal of cancer 133 (4), 929-936, 2013 | 281 | 2013 |
| Late effects of high‐dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging MB de Ruiter, L Reneman, W Boogerd, DJ Veltman, M Caan, G Douaud, ... Human brain mapping 33 (12), 2971-2983, 2012 | 270 | 2012 |
| Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer AH Honkoop, PJ Van Diest, JS De Jong, SC Linn, G Giaccone, ... British journal of cancer 77 (4), 621-626, 1998 | 260 | 1998 |
| Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene R Meuwissen, SC Linn, M van der Valk, WJ Mooi, A Berns Oncogene 20 (45), 6551-6558, 2001 | 247 | 2001 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The lancet 393 (10179), 1440-1452, 2019 | 243 | 2019 |
| Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised … MS van Ramshorst, A van der Voort, ED van Werkhoven, IA Mandjes, ... The Lancet Oncology 19 (12), 1630-1640, 2018 | 219 | 2018 |
| Validation of 70-gene prognosis signature in node-negative breast cancer JM Bueno-de-Mesquita, SC Linn, R Keijzer, J Wesseling, DSA Nuyten, ... Breast cancer research and treatment 117, 483-495, 2009 | 208 | 2009 |
| An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients MA Vollebergh, EH Lips, PM Nederlof, LFA Wessels, MK Schmidt, ... Annals of Oncology 22 (7), 1561-1570, 2011 | 203 | 2011 |
J Bueno-de-MesquitaAntes / SprinkVerified email at sprink.nl
